Muscle wasting in end-stage renal disease promulgates premature death: Established, emerging and potential novel treatment strategies

Nephrology Dialysis Transplantation

Volumn 31, Issue 7, 2016, Pages 1070-1077

  Stenvinkel, Peter ^a   Carrero, Juan Jesus ^a   Von Walden, Ferdinand ^a   Ikizler, T Alp ^b   Nader, Gustavo A ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Dialysis; Exercise; Growth hormone; Inflammation; Muscle wasting; Sarcopenia

Indexed keywords

ACTIN; GROWTH DIFFERENTIATION FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRISIN; MYOSIN; MYOSTATIN; OXYMETHOLONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN KINASE B; RECOMBINANT GROWTH HORMONE; RESVERATROL; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

AGING; BODY COMPOSITION; CELL THERAPY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; END STAGE RENAL DISEASE; ENERGY METABOLISM; GENE THERAPY; HORMONAL THERAPY; HUMAN; KINESIOTHERAPY; MITOCHONDRIAL BIOGENESIS; MORTALITY; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RESISTANCE TRAINING; REVIEW; SARCOPENIA; SKELETAL MUSCLE SATELLITE CELL; VITAMIN METABOLISM; CHRONIC KIDNEY FAILURE; COMPLICATION; PREMATURE MORTALITY; WASTING SYNDROME;

HUMANS; KIDNEY FAILURE, CHRONIC; MORTALITY, PREMATURE; WASTING SYNDROME;

EID: 84984607522     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv122     Document Type: Review

References (89)

1. Griffiths RD. Muscle mass, survival, and the elderly ICU patient. Nutrition 1996; 12: 456-458.
2. Bonanni A, Mannucci I, Verzola D et al. Protein-energy wasting and mortality in chronic kidney disease. Int J Environ Res Public Health 2011; 8: 1631-1654.
3. Martinson M, Ikizler TA, Morrell G et al. Associations of body size and body composition with functional ability and quality of life in hemodialysis patients. Clin J Am Soc Nephrol 2014; 9: 1082-1090.
4. Carrero JJ, Stenvinkel P, Cuppari L et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 2013; 23: 77-90.
5. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398.
6. Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 2014; 10: 504-516.
7. Ikizler TA, Cano NJ, Franch H et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int 2013; 84: 1096-1107.
8. Mitch WE, Du J. Cellular mechanisms causing loss of muscle mass in kidney disease. Semin Nephrol 2004; 24: 484-487.
9. Chen F, Lam R, Shaywitz D et al. Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia SarcopeniaMuscle 2011; 2: 45-56.
10. Baumgartner RN, Waters DL, Gallagher D et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123-136.
11. Morley JE, Abbatecola AM, Argiles JM et al. Sarcopenia with limited mobility: An international consensus. J Am Med Dir Assoc 2011; 12: 403-409.
12. Sharma D, Hawkins M, Abramowitz MK. Association of sarcopenia with eGFR and misclassification of obesity in adults with CKD in the United States. Clin J Am Soc Nephrol 2014; 9: 2079-2088.
13. Batsis JA, Barre LK, Mackenzie TA et al. Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc 2013; 61: 974-980.
14. Isoyama N, Qureshi AR, Avesani CM et al. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol 2014; 9: 1720-1728.
15. Lee DY, Wetzsteon RJ, Zemel BS et al. Muscle torque relative to crosssectional area and the functional muscle-bone unit in children and adolescents with chronic disease. J Bone Miner Res 2015; 30: 563-571.
16. Shimokata H, Ando F, Yuki A et al. Age-related changes in skeletal muscle mass among community-dwelling Japanese: A 12-year longitudinal study. Geriatr Gerontol Int 2014; 14(Suppl 1): 85-92.
17. Chang CI, Huang KC, Chan DC et al. The impacts of sarcopenia and obesity on physical performance in the elderly. Obes Res Clin Pract 2014 [Epub ahead of print].
18. Sakkas GK, Kent-Braun JA, Doyle JW et al. Effect of diabetes mellitus on muscle size and strength in patients receiving dialysis therapy. Am J Kidney Dis 2006; 47: 862-869.
19. Van Craenenbroeck AH, Van Craenenbroeck EM, Kouidi E et al. Vascular effects of exercise training in CKD: current evidence and pathophysiological mechanisms. Clin J Am Soc Nephrol 2014; 9: 1305-1318.
20. Rossi AP, Burris DD, Lucas FL et al. Effects of a renal rehabilitation exercise program in patients with CKD: A randomized, controlled trial. Clin J Am Soc Nephrol 2014; 9: 2052-2058.
21. Watson EL, Greening NJ, Viana JL et al. Progressive resistance exercise training in CKD: A feasibility study. Am J Kidney Dis 2014; In Press.
22. Howden EJ, Coombes JS, Strand H et al. Exercise training in CKD: Efficacy, adherence, and safety. Am J Kidney Dis 2015; 65: 583-591.
23. Dong J, Sundell MB, Pupim LB et al. The effect of resistance exercise to augment long- Term benefits of intradialytic oral nutritional supplementation in chronic hemodialysis patients. J Ren Nutr 2011; 21: 149-159.
24. Majchrzak KM, Pupim LB, Flakoll PJ et al. Resistance exercise augments the acute anabolic effects of intradialytic oral nutritional supplementation. Nephrol Dial Transplant 2008; 23: 1362-1369.
25. Cheema B, Abas H, Smith B et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: The progressive exercise for anabolism in kidney disease (PEAK) study. Am J Kidney Dis 2007; 50: 574-584.
26. Storer T, Casaburi R, Sawelson S et al. Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. Nephrol Dial Transpl 2005; 20: 1429-1437.
27. Viana JL, Kosmadakis GC, Watson EL et al. Evidence for anti-inflammatory effects of exercise in CKD. J Am Soc Nephrol 2014; 25: 2121-2130.
28. Gielen S, Adams V, Möbius-Winkler S et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 861-868.
29. Boström P, Wu J, Jedrychowski MP et al. A PGC1- A-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468.
30. Timmons JA, Baar K, Davidsen PK et al. Is irisin a human exercise gene? Nature 2012; 488: E9-10.
31. Norheim F, Langleite TM, Hjorth M et al. The effects of acute and chronic exercise on PGC-1a, irisin and browning of subcutaneous adipose tissue in humans. FEBS J 2014; 281: 739-749.
32. Ebert T, Focke D, Petroff D et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol 2014; 170: 501-506.
33. Erickson HP. Irisin and FNDC5 in retrospect. An excercise hormone or a transmembrane receptor? Adipocyte 2013; 4: 289-293.
34. FanW, Atkins AR, Yu RTet al. Road to exercise mimetics: Targeting nuclear receptors in skeletal muscle. J Mol Endocrinol 2013; 51: T87-T100.
35. Denham J, Marques FZ, O'Brien BJ et al. Exercise: putting action into our epigenome. Sports Med 2014; 44: 189-209.
36. Stratton RJ, Bircher G, Fouque D et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: A systematic reviewand meta- Analysis. Am J Kidney Dis 2005; 46: 387-405.
37. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-2084.
38. Price SR, England BK, Bailey JL et al. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am J Physiol 1994; 267: C955-C960.
39. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 1999; 281: 1275-1281.
40. Mori A, Nishino T, Obata Y et al. The effect of active vitamin D administration on muscle mass in hemodialysis patients. Clin Drug Investig 2013; 33: 837-846.
41. Garibotto G, Barreca A, Russo R et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99: 97-105.
42. Pupim LB, Flakoll PJ, Yu C et al. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 2005; 82: 1235-1243.
43. Tonkin J, Villarroya F, Puri PL et al. SIRT1 signaling as potential modulator of skeletal muscle diseases. Curr Opin Pharmacol 2012; 12: 372-376.
44. McGregor RA, Poppitt SD, Cameron-Smith D. Role of microRNAs in the age-related changes in skeletal muscle and diet or exercise interventions to promote healthy aging in humans. Ageing Res Rev 2014; 17: 25-33.
45. Jang YC, Sinha M, Cerletti M et al. Skeletal muscle stem cells: Effects of aging and metabolism on muscle regenerative function. Cold Spring Harb Symp Quant Biol 2011; 76: 101-111.
46. Zhang L, Rajan V, Lin E et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25: 1653-1663.
47. Sinha M, Jang YC, Oh J et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014; 344: 649-652.
48. Stenvinkel P. Can treating persistent inflammation limit protein energy wasting? Semin Dial 2012; 26: 16-39.
49. Zykovich A, Hubbard A, Flynn JM et al. Genome-wide DNA methylation changes with age in disease-free human skeletal muscle. Aging Cell 2014; 13: 360-366.
50. Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transpl 2012; 27: 4030-4041.
51. Carrero JJ, Barany P, Yilmaz MI et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transpl 2012; 27: 709-715.
52. Cigarrán S, Pousa M, Castro MJ et al. Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. J Renal Nutr 2013; 23: E89-e95.
53. Supasyndh O, Satirapoj B, Aramwit P et al. Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 271-279.
54. Johansen KL, Painter PL, Sakkas GK et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 2006; 17: 2307-2314.
55. Goldsmith DJA, Massy ZA, Brandenburg V. The uses and abuses of vitamin D compunds in chronic kidney disease-mineral bone disease (CKD-MBD). Semin Nephrol 2014; 34: 660-668.
56. Garcia LA, King KK, Ferrini MG et al. 1, 25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 2011; 152: 2976-2986.
57. Miyamoto T, Carrero J, Qureshi AR et al.Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bonemineral density, inflammation, and survival. Clin J Am Soc Nephrol 2011; 6: 1001-1008.
58. Liu G, Lu L, Sun Q et al. Poor vitamin D status is prospectively associated with greater muscle mass loss in middle- Aged and elderly Chinese individuals. J Acad Nutr Diet 2014; 114: 1544-1551.
59. Sanders KM, Scott D, Ebeling PR. Vitamin D deficiency and its role in muscle-bone interactions in the elderly. Curr Osteoporos Rep 2014; 12: 74-81.
60. Mehls O, Tonshoff B, Blum WF et al. Growth hormone and insulin-like growth factor I in chronic renal failure-pathophysiology and rationale for growth hormone treatment. Acta Paediatr Scand Suppl 1990; 370: 28-34.
61. Trobec K, von Haehling A, Anker SD et al. Growth hormone, insulin-like growth factor 1, and signaling - A pharmacological target in body wasting and cachexia. J Cachexia Sarcopenia Muscle 2011; 2: 191-200.
62. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50: 343-357.
63. Garibotto G, Russo R, Sofia A et al. Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. Kidney Int 2008; 74: 937-945.
64. Chan W, Valerie KC, Chan JCM. Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake. Kidney Int 1993; 43: 790-795.
65. Sun DF, Zheng Z, Tummala P et al. Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. J Am Soc Nephrol 2004; 15: 2630-2636.
66. Iglesias P, Diez JJ, Fernandez-Reyes MJ et al. Recombinant human growth hormone therapy in malnourished dialysis patients: A randomized controlled study. Am J Kidney Dis 1998; 32: 454-463.
67. Kotzmann H, Yilmaz N, Lercher P et al. Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int 2001; 60: 1578-1585.
68. Niemczyk S, Sikorska H, Wiecek A et al. A super- Agonist of growth hormone-releasing hormone causes rapid improvement of nutritional status in patients with chronic kidney disease. Kidney Int 2010; 77: 450-458.
69. Kopple JD, Cheung AK, Christiansen JS et al. OPPORTUNITY: A large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transpl 2011; 26: 4095-4103.
70. Powers SK, Wiggs MP, Duarte JA et al.Mitochondrial signaling contributes to disuse muscle atrophy. Am J Physiol Endocrinol Metab 2012; 303: E31-E39.
71. Chen KH, Cheng ML, Jing YH et al. Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2011; 301: E853-E863.
72. Zaza G, Granata S, Masola V et al. Downregulation of nuclear-encoded genes of oxidative metabolism in dialyzed chronic kidney disease patients. PloS One 2013; 8: E77847.
73. Agudelo LZ, Femenía T, Orhan F et al. Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 2014; 159: 33-45.
74. Palmer SC, Vecchio M, Craig JC et al. Association between depression and death in people with CKD: A meta- Analysis of cohort studies. Am J Kidney Dis 2013; 62: 493-505.
75. Mak RH, Ikizler AT, Kovesdy C et al. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011; 2: 9-25.
76. Mercken EM, Mitchell SJ, Martin-Montalvo A et al. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 2014; 13: 787-796.
77. Lee D, Goldberg AL. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J Biol Chem 2013; 288: 30515-30526.
78. Kooman JP, Kotanko P, Schols AM et al. Chronic kidney disease and premature ageing. Nat Rev Nephrol 2014; 10: 732-742.
79. Renault V, Thornell LE, Eriksson PO et al. Regenerative potential of human skeletal muscle during aging. Aging Cell 2002; 1: 132-139.
80. Lanza D, Perna AF, Oliva A et al. Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells. PLoS One 2015; 10: E0116468.
81. Jourde-Chiche N, Dou L, Sabatier F et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009; 7: 1576-1584.
82. Noh H, Yu MR, Kim HJ et al. Uremia induces functional incompetence of bone marrow-derived stromal cells. Nephrol Dial Transplant 2012; 27: 218-225.
83. Negroni E, Gidaro T, Bigot A et al. Stem cells and muscle diseases: Advances in cell therapy strategies. Neuropathol Appl Neurobiol 2014; 41: 270-287.
84. Yuen DA, Kuliszewski MA, Liao C et al. Nocturnal hemodialysis is associated with restoration of early-outgrowth endothelial progenitor-like cell function. Clin J Am Soc Nephrol 2011; 6: 1345-1353.
85. Elabd C, Cousin W, Upadhyayula P et al. Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration. Nat Commun 2014; 5: 4082.
86. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 2010; 23: 498-509.
87. Han HQ, Zhou X, Mitch WE et al. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol 2013; 45: 2333-2347.
88. Zhang L, Pan J, Dong Y et al. Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab 2013; 18: 368-379.
89. Loffredo FS, Steinhauser ML, Jay SM et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013; 153: 828-839.